Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-751 Safety, Tolerability, and Food Effect in Parkinson's Disease
NCT04295642Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tavapadon in Parkinson's disease (PD) (2 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration-time curve and 2 more. Started Jan 2020; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04295642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295642.